{
  "created_at": "Fri Jan 28 12:3:41 +0000 2022",
  "id_str": "1487027367772098568",
  "full_text": "America’s drugs regulator may approve MDMA for treating PTSD as early as next year https://t.co/eJEiDPkCm3",
  "display_text_range": [
    0,
    106
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/eJEiDPkCm3",
        "expanded_url": "https://econ.st/349yACC",
        "display_url": "econ.st/349yACC",
        "indices": [
          83,
          106
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 23,
  "favorite_count": 105,
  "possibly_sensitive": false,
  "original_created_at": "Fri Jan 28 11:38:46 +0000 2022",
  "localize": [
    {
      "locale": "ja",
      "full_text": "アメリカの薬物規制当局が、早ければ来年にもPTSDの治療にMDMAを承認する可能性 https://t.co/eJEiDPkCm3"
    },
    {
      "locale": "zh",
      "full_text": "美国药品监管机构可能最早于明年批准MDMA用于治疗创伤后应激障碍https://t.co/eJEiDPkCm3"
    },
    {
      "locale": "zh-Hant",
      "full_text": "美國藥品監管機構可能最早於明年批准MDMA用於治療創傷後應激障礙https://t.co/eJEiDPkCm3"
    }
  ]
}